The availability of VolitionRx's Nu.Q Vet Cancer Test in clinics across the US and Europe significantly broadens the product's market reach and accessibility, potentially leading to increased usage and revenue. Partnering with Antech, a well-known name in the veterinary industry, could also enhance credibility and adoption rates among veterinarians and pet owners. This strategic move is likely to have a positive short-term impact on VolitionRx's stock price due to the potential for increased sales and market penetration.